United States: WilmerHale Counsels Tokai Pharmaceuticals In Share Purchase Agreement With Otic Pharma
Last Updated: January 6 2017

Tokai Pharmaceuticals Inc. and Otic Pharma Ltd., a privately held, clinical-stage pharmaceutical company focusing on the development and commercialization of products for disorders of the ear, nose and throat, announced that the two companies—together with the shareholders of Otic Pharma—have entered into a definitive share purchase agreement under which the shareholders of Otic Pharma will become the majority owners of Tokai.

The WilmerHale deal team included Partners Hal Leibowitz, Stuart Falber, Belinda Juran, Bill Caporizzo and Amy Null; Counsel Michael Welhouse; Senior Associate Ryan Mitteness; and Associate Andrea Sorrentino.

Read Tokai Pharmaceuticals' press release for more information.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Press Releases from this Firm
Recent Content from this Firm
By Alan Wilson, Jonathan Wolfman
By Ambassador Charlene Barshefsky, Naboth van den Broek, David Ross, Patrick J. McLain, David Horn
By Frederick Saugman
By Bill Warren
By Michael Connor, H. David Gold, Sarah Judkins, Andrew L. Spielman
By Lester Ross, Tingting Liu
By H. David Gold, Rachel Jacobson, Heidi K. Ruckriegle
By Joseph Mueller, Thomas Saunders, Leslie Pearlson
By WilmerHale
By Robert D. Burke, A. William Caporizzo, Julie Hogan Rodgers, Meghan Walsh
Font Size: